Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study.

Tierney JF, Fisher DJ, Burdett S, Stewart LA, Parmar MKB.

PLoS Med. 2020 Jan 31;17(1):e1003019. doi: 10.1371/journal.pmed.1003019. eCollection 2020 Jan.

2.

Should 68Ga-DOTATATE PET/CT be Performed Routinely in Patients with Neuroendocrine Tumors Before Surgical Resection?

Babazadeh NT, Schlund DJ, Cornelius T, Singh JS, Tierney JF, Chen M, Keutgen XM.

World J Surg. 2020 Feb;44(2):604-611. doi: 10.1007/s00268-019-05216-3.

PMID:
31576440
3.

Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients?

Chivukula SV, Tierney JF, Hertl M, Poirier J, Keutgen XM.

Surgery. 2020 Jan;167(1):180-186. doi: 10.1016/j.surg.2019.04.061. Epub 2019 Sep 16.

PMID:
31537303
4.

National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress?

Tierney JF, Chivukula SV, Poirier J, Pappas SG, Schadde E, Hertl M, Kebebew E, Keutgen X.

J Clin Endocrinol Metab. 2019 Dec 1;104(12):5948-5956. doi: 10.1210/jc.2019-00915.

PMID:
31361313
5.

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses.

Xie W, Halabi S, Tierney JF, Sydes MR, Collette L, Dignam JJ, Buyse M, Sweeney CJ, Regan MM.

JNCI Cancer Spectr. 2019 Feb 6;3(1):pkz002. doi: 10.1093/jncics/pkz002. eCollection 2019 Mar. Review.

6.

Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases.

Tierney JF, Poirier J, Chivukula S, Pappas SG, Hertl M, Schadde E, Keutgen X.

Int J Endocrinol. 2019 Mar 12;2019:9871319. doi: 10.1155/2019/9871319. eCollection 2019.

7.

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.

Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, van Andel G, Clarke NW, Hulshof MC, James ND, Parker CC, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Verhagen PC, Tierney JF; STOPCAP M1 Radiotherapy Collaborators.

Eur Urol. 2019 Jul;76(1):115-124. doi: 10.1016/j.eururo.2019.02.003. Epub 2019 Feb 28.

8.

Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.

Tierney JF, Vale CL, Parelukar WR, Rydzewska L, Halabi S.

Eur Urol Focus. 2019 Mar;5(2):137-143. doi: 10.1016/j.euf.2019.01.005. Epub 2019 Feb 1.

PMID:
30713089
9.

Gastric Outlet Obstruction after Subtotal Cholecystectomy.

Tierney JF, Qureshi J.

Am Surg. 2018 Jul 1;84(7):e217-e218. No abstract available.

PMID:
30454326
10.

68Gallium-DOTATATE positron emission tomography-computed tomography (PET CT) changes management in a majority of patients with neuroendocrine tumors.

Tierney JF, Kosche C, Schadde E, Ali A, Virmani S, Pappas SG, Poirier J, Keutgen XM.

Surgery. 2019 Jan;165(1):178-185. doi: 10.1016/j.surg.2018.03.030. Epub 2018 Nov 8.

PMID:
30415869
11.

Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: An exploratory study.

Tierney JF, Vogle A, Poirier J, Min IM, Finnerty B, Zarnegar R, Pappas SG, Scognamiglio T, Ghai R, Gattuso P, Fahey TJ 3rd, Keutgen XM.

Surgery. 2019 Jan;165(1):196-201. doi: 10.1016/j.surg.2018.04.086. Epub 2018 Nov 7.

PMID:
30413322
12.

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data.

Navani N, Fisher DJ, Tierney JF, Stephens RJ, Burdett S; NSCLC Meta-analysis Collaborative Group.

Chest. 2019 Mar;155(3):502-509. doi: 10.1016/j.chest.2018.10.020. Epub 2018 Oct 26.

13.

Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.

Tierney JF, Chivukula SV, Wang X, Pappas SG, Schadde E, Hertl M, Poirier J, Keutgen XM.

Surgery. 2019 Mar;165(3):644-651. doi: 10.1016/j.surg.2018.09.006. Epub 2018 Oct 23.

PMID:
30366604
14.

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.

Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Rydzewska LH, Sweeney CJ, Spears MR, Sydes MR, Tierney JF.

Ann Oncol. 2018 May 1;29(5):1249-1257. doi: 10.1093/annonc/mdy071.

15.

A framework for identifying treatment-covariate interactions in individual participant data network meta-analysis.

Freeman SC, Fisher D, Tierney JF, Carpenter JR.

Res Synth Methods. 2018 Sep;9(3):393-407. doi: 10.1002/jrsm.1300. Epub 2018 Jun 11.

16.

Response to letter commenting on published paper: Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

Rydzewska LHM, Burdett S, Vale CL, Parmar MKB, Tierney JF.

Eur J Cancer. 2018 May;94:218-219. doi: 10.1016/j.ejca.2018.02.002. Epub 2018 Mar 13. No abstract available.

PMID:
29548532
17.
18.

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF; STOPCaP Abiraterone Collaborators.

Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8. Review.

19.

The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials.

Clayton GL, Smith IL, Higgins JPT, Mihaylova B, Thorpe B, Cicero R, Lokuge K, Forman JR, Tierney JF, White IR, Sharples LD, Jones HE.

Trials. 2017 May 15;18(1):219. doi: 10.1186/s13063-017-1955-y.

20.

Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?

Fisher DJ, Carpenter JR, Morris TP, Freeman SC, Tierney JF.

BMJ. 2017 Mar 3;356:j573. doi: 10.1136/bmj.j573. No abstract available.

21.

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Sweeney CJ, Sydes MR, Tombal B, Tierney JF; STOpCaP Steering Group.

Lancet Oncol. 2016 Feb;17(2):243-256. doi: 10.1016/S1470-2045(15)00489-1. Epub 2015 Dec 21. Review. Erratum in: Lancet Oncol. 2016 Feb;17(2):e46.

22.

Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on Their Use.

Tierney JF, Vale C, Riley R, Smith CT, Stewart L, Clarke M, Rovers M.

PLoS Med. 2015 Jul 21;12(7):e1001855. doi: 10.1371/journal.pmed.1001855. eCollection 2015 Jul.

23.

How individual participant data meta-analyses have influenced trial design, conduct, and analysis.

Tierney JF, Pignon JP, Gueffyier F, Clarke M, Askie L, Vale CL, Burdett S; Cochrane IPD Meta-analysis Methods Group.

J Clin Epidemiol. 2015 Nov;68(11):1325-35. doi: 10.1016/j.jclinepi.2015.05.024. Epub 2015 Jun 3.

24.

Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.

Wei Y, Royston P, Tierney JF, Parmar MK.

Stat Med. 2015 Sep 20;34(21):2881-98. doi: 10.1002/sim.6556. Epub 2015 Jun 23.

25.

Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement.

Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group.

JAMA. 2015 Apr 28;313(16):1657-65. doi: 10.1001/jama.2015.3656.

PMID:
25919529
26.

Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials.

Vale CL, Burdett S, Fisher DJ, Navani N, Parmar MK, Copas AJ, Tierney JF.

Clin Lung Cancer. 2015 May;16(3):173-182.e4. doi: 10.1016/j.cllc.2014.11.007. Epub 2014 Nov 22. Review.

27.

Measuring the impact of methodological research: a framework and methods to identify evidence of impact.

Brueton VC, Vale CL, Choodari-Oskooei B, Jinks R, Tierney JF.

Trials. 2014 Nov 27;15:464. doi: 10.1186/1745-6215-15-464.

28.

Preoperative chemotherapy for non-small-cell lung cancer--authors' reply.

Burdett S, Rydzewska LH, Tierney JF, Auperin A, Pignon JP, Le Pechoux C, Le Chevalier T, van Meerbeeck J.

Lancet. 2014 Jul 19;384(9939):233. doi: 10.1016/S0140-6736(14)61209-5. No abstract available.

PMID:
25042232
29.

Response to: Practical methods for incorporating summary time-to-event data into meta. Authors' reply.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR.

Trials. 2013;14:391. Epub 2013 Nov 19. No abstract available.

PMID:
24511621
30.

Strategies to improve retention in randomised trials: a Cochrane systematic review and meta-analysis.

Brueton VC, Tierney JF, Stenning S, Meredith S, Harding S, Nazareth I, Rait G.

BMJ Open. 2014 Feb 4;4(2):e003821. doi: 10.1136/bmjopen-2013-003821. Review.

31.

Use of strategies to improve retention in primary care randomised trials: a qualitative study with in-depth interviews.

Brueton VC, Stevenson F, Vale CL, Stenning SP, Tierney JF, Harding S, Nazareth I, Meredith S, Rait G.

BMJ Open. 2014 Jan 24;4(1):e003835. doi: 10.1136/bmjopen-2013-003835.

32.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S; Surrogate Lung Project Collaborative Group.

Lancet Oncol. 2013 Jun;14(7):619-26. doi: 10.1016/S1470-2045(13)70158-X. Epub 2013 May 14.

33.
34.

A closer look at the effects of postoperative radiotherapy by stage and nodal status: updated results of an individual participant data meta-analysis in non-small-cell lung cancer.

Burdett S, Rydzewska L, Tierney JF, Fisher DJ; PORT Meta-analysis Trialist Group.

Lung Cancer. 2013 Jun;80(3):350-2. doi: 10.1016/j.lungcan.2013.02.005. Epub 2013 Feb 27. No abstract available.

PMID:
23453644
35.

Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61:443-51.

Sydes MR, Vale C, Kneebone A, Pearse M, Richaud P, Tierney JF, Parker CC.

Eur Urol. 2012 Dec;62(6):e99. doi: 10.1016/j.eururo.2012.09.003. Epub 2012 Sep 11. No abstract available.

PMID:
23018161
36.

Evaluation of patient involvement in a systematic review and meta-analysis of individual patient data in cervical cancer treatment.

Vale CL, Tierney JF, Spera N, Whelan A, Nightingale A, Hanley B.

Syst Rev. 2012 May 7;1:23. doi: 10.1186/2046-4053-1-23.

37.

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.

Vale CL, Tierney JF, Fisher D, Adams RA, Kaplan R, Maughan TS, Parmar MK, Meade AM.

Cancer Treat Rev. 2012 Oct;38(6):618-25. doi: 10.1016/j.ctrv.2011.11.002. Epub 2011 Nov 26. Review.

PMID:
22118887
38.

Individual patient data meta-analysis of time-to-event outcomes: one-stage versus two-stage approaches for estimating the hazard ratio under a random effects model.

Bowden J, Tierney JF, Simmonds M, Copas AJ, Higgins JP.

Res Synth Methods. 2011 Sep;2(3):150-62. doi: 10.1002/jrsm.45.

PMID:
26061783
39.

Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?

Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G.

Br J Cancer. 2011 Oct 11;105(8):1107-13. doi: 10.1038/bjc.2011.289. Epub 2011 Aug 16. Review.

40.

Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics.

Bowden J, Tierney JF, Copas AJ, Burdett S.

BMC Med Res Methodol. 2011 Apr 7;11:41. doi: 10.1186/1471-2288-11-41.

41.

A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners.

Fisher DJ, Copas AJ, Tierney JF, Parmar MK.

J Clin Epidemiol. 2011 Sep;64(9):949-67. doi: 10.1016/j.jclinepi.2010.11.016. Epub 2011 Mar 16. Review.

PMID:
21411280
42.

One-stage parametric meta-analysis of time-to-event outcomes.

Siannis F, Barrett JK, Farewell VT, Tierney JF.

Stat Med. 2010 Dec 20;29(29):3030-45. doi: 10.1002/sim.4086. Epub 2010 Oct 20.

43.

Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit.

Vale CL, Tierney JF, Davidson SE, Drinkwater KJ, Symonds P.

Clin Oncol (R Coll Radiol). 2010 Sep;22(7):590-601. doi: 10.1016/j.clon.2010.06.002. Epub 2010 Jul 1.

44.

Late complications from chemoradiotherapy for cervical cancer: reflections from cervical cancer survivors 10 years after the national cancer institute alert.

Vale C, Nightingale A, Spera N, Whelan A, Hanley B, Tierney JF.

Clin Oncol (R Coll Radiol). 2010 Sep;22(7):588-9. doi: 10.1016/j.clon.2010.05.017. Epub 2010 Jun 15. No abstract available.

PMID:
20554439
45.

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF, Tribodet H, van Meerbeeck J.

Lancet. 2010 Apr 10;375(9722):1267-77. doi: 10.1016/S0140-6736(10)60059-1. Epub 2010 Mar 24.

46.

Concomitant and neoadjuvant chemotherapy for cervical cancer.

Tierney JF, Vale C, Symonds P.

Clin Oncol (R Coll Radiol). 2008 Aug;20(6):401-16. doi: 10.1016/j.clon.2008.04.003. Epub 2008 Jun 20. Review.

PMID:
18571391
47.

Practical methods for incorporating summary time-to-event data into meta-analysis.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR.

Trials. 2007 Jun 7;8:16.

48.

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, Green JA.

Ann Oncol. 2007 Mar;18(3):409-20. Epub 2006 Dec 5. Review.

49.

Meta-analysis of individual patient data from randomized trials: a review of methods used in practice.

Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG.

Clin Trials. 2005;2(3):209-17.

PMID:
16279144
50.

Preoperative radiotherapy for esophageal carcinoma.

Arnott SJ, Duncan W, Gignoux M, Hansen HS, Launois B, Nygaard K, Parmar MK, Rousell A, Spilopoulos G, Stewart G, Tierney JF, Wang M, Rhugang Z; Oeosphageal Cancer Collaborative Group.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001799. Review.

PMID:
16235286

Supplemental Content

Loading ...
Support Center